Finerenone

Finerenone (BAY-948862) 是一种选择性、具有口服活性的、非甾体类盐皮质激素受体拮抗剂 (IC50=18 nM)。与糖皮质激素受体、雄激素受体和孕酮受体相比,它表现出良好的选择性 (>500-fold)。它在心肾疾病研究中具有潜在的应用前景,如 2 型糖尿病和慢性肾脏疾病。

CAS号

1050477-31-0

分子式

C21H22N4O3

主要靶点

Glucocorticoid Receptor

仅限科研使用

Cat No : CM05142

Print datasheet

Synonyms

BAY948862|BAY-948862|非奈利酮|BAY94-8862|BAY 94-8862|BAY-94-8862|BAY 948862



产品信息

Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the treatment of chronic heart failure. Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).

CAS号 1050477-31-0
分子式 C21H22N4O3
主要靶点 Glucocorticoid Receptor
主要通路 内分泌与激素
分子量 378.43
纯度 99.72%, 此纯度可做参考,具体纯度与批次有关系,可咨询客服
储存条件 Powder: -20°C for 3 years | In solvent: -80°C for 1 year
别名 BAY948862|BAY-948862|非奈利酮|BAY94-8862|BAY 94-8862|BAY-94-8862|BAY 948862

靶点活性

Mineralocorticoid Receptor:18 nM

溶解度

DMSO:60 mg/ml (158.55 mM),H2O:Insoluble

参考文献

1.George L Bakris , Rajiv Agarwal ,et al.Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.JAMA. 2015 Sep 1;314(9):884-94. 
2.Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016 Jan;18(1):28-37. doi: 10.1002/ejhf.444. Epub 2015 Dec 3. Review. PubMed PMID: 26634965.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
=
×
×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
×
=
×
C1   V1   C2   V2